Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Machine learning-generated miRNA/isomiR classifiers with miR-148-3p (connections to BCL2 and MYC) may predict durable (≥6 mos) response, PFS (HR 33.09) and OS (3.81) in relapsed/refractory pts receiving daratumumab regimens.”
Title: Circulating extracellular vesicle isomiR signatures predict therapy response in patients with multiple myeloma
Authors: Cristina Gómez-Martín, Esther E.E. Drees, Monique A.J. van Eijndhoven, Nils J. Groenewegen, Steven Wang, Sandra A.W.M. Verkuijlen, Jan R.T. van Weering, Ernesto Aparicio-Puerta, Leontien Bosch, Kris A. Frerichs, Christie P.M. Verkleij, Marie J. Kersten, Josée M. Zijlstra, Daphne de Jong, Catharina G.M. Groothuis-Oudshoorn, Michael Hackenberg, Johan R. de Rooij, Niels W.C.J. van de Donk, D. Michiel Pegtel
You can read the Full Article in Cell Reports Medicine.
You can find more posts featuring Robert Orlowski on OncoDaily.
